E-viri
Recenzirano
-
Ikeda, Hiroki; Watanabe, Tsunamasa; Atsukawa, Masanori; Toyoda, Hidenori; Takaguchi, Koichi; Nakamuta, Makoto; Matsumoto, Nobuyuki; Okuse, Chiaki; Tada, Toshifumi; Tsutsui, Akemi; Yamashita, Naoki; Kondo, Chisa; Hayama, Korenobu; Kato, Keizo; Itokawa, Norio; Arai, Taeang; Shimada, Noritomo; Asano, Toru; Uojima, Haruki; Ogawa, Chikara; Mikami, Shigeru; Ikegami, Tadashi; Fukunishi, Shinya; Asai, Akira; Iio, Etsuko; Tsubota, Akihito; Hiraoka, Atsushi; Nozaki, Akito; Okubo, Hironao; Tachi, Yoshihiko; Moriya, Akio; Oikawa, Tsunekazu; Matsumoto, Yoshihiro; Tsuruoka, Shuichi; Tani, Joji; Kikuchi, Kan; Iwakiri, Katsuhiko; Tanaka, Yasuhito; Kumada, Takashi
Journal of viral hepatitis, November 2019, Letnik: 26, Številka: 11Journal Article
Based on high efficacy and safety demonstrated in clinical trials, treatment with glecaprevir/pibrentasvir (G/P) for 8 weeks is recommended for hepatitis C virus (HCV)–infected patients who are direct‐acting antiviral (DAA) naïve, genotype 1 or 2, and noncirrhotic. The aim of this study was to validate real‐world experience with 8‐week G/P treatment in Japan. We conducted a prospective observational cohort study in 554 patients who underwent 8‐week treatment from among 1,022 patients who initiated G/P therapy. The majority (54.5%) were male, with a median age of 66 years, and HCV genotype distribution was genotype 1, 43.8%; genotype 2, 55.3%; and mixed subtype, 0.9%. Overall, the sustained virologic response rate at 12 weeks (SVR12) was 92.8% (530/571) in the intention‐to‐treat population and 99.3% (526/530) in the per‐protocol population. The SVR12 rates by subgroups were as follows: subtype 1a, 100% (6/6); 1b, 100% (189/189); 2a, 99.3% (150/151); 2b, 99.0% (103/104); and mixed subtype, 50% (2/4). Among four patients with virologic failure following 8‐week treatment with G/P, none had baseline polymorphisms or treatment‐emergent amino acid substitutions in NS3. However, 2 of 4 patients with virologic failure had treatment‐emergent amino acid substitutions in NS5A. Adverse events (AEs) were reported in 21.5% of patients and 1.2% of patients discontinued due to drug‐related AEs. In conclusion, G/P treatment for 8 weeks was safe and effective for DAA‐naïve noncirrhotic genotype 1 or 2 patients in a real‐world clinical setting in Japan.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.